Guardian Pharmacy Services, Inc. GRDN
- Market cap
- $2.7B
- P/E
- 39.2×
Follow GRDN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 14.16 | 17.78 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 25.74 | 37.43 |
High Price
|
|||
| — | — | — | — | — | — | — | 3,200 | 3,400 | 3,600 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 1,046 | 1,228 | 1,449 |
Revenue
|
|||
| — | — | — | — | — | — | — | 19.91% | 19.89% | 20.21% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | 38 | (66) | 73 |
EBT
|
|||
| — | — | — | — | — | — | — | 3.61% | (5.41%) | 5.07% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | 38 | (71) | 49 |
Net Income
|
|||
| — | — | — | — | — | — | — | 18 | 20 | 22 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 0.00 | 19.81 | 23.22 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (1.77) | 0.79 |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.93 | 1.61 |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | (0.26) | (0.31) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.67 | 1.29 |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 2.42 | 3.49 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 0 | 62 | 62 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 38.09 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 1.02 | 1.30 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 8.38 | 8.61 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 1.05 | 1.28 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | 0.00 | 31.02 | 22.92 |
EV/FCF
|
|||
| — | — | — | — | — | — | — | 71 | 58 | 100 |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (15) | (16) | (20) |
Capex
|
|||
| — | — | — | — | — | — | — | 56 | 42 | 81 |
FCF
|
|||
| — | — | — | — | — | — | — | (8) | 8 | 61 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 28 | — | — |
Total Debt
|
|||
| — | — | — | — | — | — | — | 27 | (5) | (66) |
Net Debt
|
|||
| — | — | — | — | — | — | — | 60 | 150 | 218 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | (37.18%) | 13.42% |
ROA
|
|||
| — | — | — | — | — | — | — | 29.38% | (27.06%) | 29.83% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | (104.89%) | 26.76% |
ROE
|
|||
Guardian Pharmacy Services, Inc. peers in Medical Care Facilities
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BKD Brookdale Senior Living Inc. | $2.6B | 0.0× | Compare |
| AVAH Aveanna Healthcare Holdings Inc. | $2.7B | 9.5× | Compare |
| ACHC Acadia Healthcare Company, Inc. | $2.6B | 0.0× | Compare |
| ADUS Addus HomeCare Corporation | $2.1B | 19.9× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MD Pediatrix Medical Group, Inc. | $2.1B | 12.6× | Compare |
| OPCH Option Care Health, Inc. | $3.4B | 17.3× | Compare |
| NHC National HealthCare Corporation | $3.5B | 25.2× | Compare |
| SGRY Surgery Partners, Inc. | $1.9B | 0.0× | Compare |
Guardian Pharmacy Services, Inc. (GRDN) key facts
- Guardian Pharmacy Services, Inc. (GRDN) is a Medical Care Facilities company in the Healthcare sector, listed on the New York Stock Exchange.
- Guardian Pharmacy Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.9% from fiscal 2024.
- As of September 25, 2026, GRDN traded at $41.21, a market capitalization of $2.7 billion.
- Return on equity was 26.8% and debt-to-equity 0.00.
Guardian Pharmacy Services, Inc. (GRDN) Latest News
1 Sep
Guardian Pharmacy Services acquires assets of Tennessee-based Nautilus Pharmacy. Asset purchase expands operations and competitive reach in Tennessee.
13 Aug
Guardian Pharmacy Services (GRDN) released its Q2 2026 earnings call transcript covering financial results and business updates. Q2 earnings details and forward outlook can moderately shift investor views on financial performance.
9 Aug
Guardian Pharmacy Services (GRDN) posts strong results and raises outlook, driving a positive recast of its valuation. Strong results combined with higher outlook directly improve GRDN financial trajectory and investor sentiment.
8 Aug
Guardian Pharmacy Services raised 2026 revenue guidance and expanded its footprint, driving a 10.9% stock gain. Raising long-term revenue guidance combined with footprint expansion indicates major strategic progress likely to improve financial trajectory and investor outlook.
Guardian Pharmacy Services held its Q2 earnings call, outlining financial results, operational metrics, and strategic outlook for the period. Q2 earnings call supplies updated financial and operational data that can moderately shift market views on near-term performance.
7 Aug
Guardian Pharmacy Services, Inc. (GRDN) raised its 2026 outlook after reporting strong second quarter results. Raising 2026 outlook after strong quarterly results signals higher growth expectations and lifts investor sentiment.
Guardian Pharmacy Services Inc (GRDN) raised its full-year guidance after reporting Q2 2026 results. Raised guidance signals stronger future financial performance for Guardian Pharmacy Services.
6 Aug
Guardian Pharmacy Services reported second quarter 2026 financial results and raised full-year guidance. Raised full-year guidance after quarterly results signals stronger outlook that can lift valuation and investor sentiment.
1 Jul
Guardian Pharmacy Services acquires Wellness Concepts, expanding its Virginia operations. Acquisition of Wellness Concepts expands Guardian Pharmacy Services' Virginia presence and operational scale.
22 Jun
Guardian Pharmacy Services, Inc. announced leadership transitions. Leadership transitions can shift strategy and affect operational execution.
14 May
Guardian Pharmacy Services (NYSE:GRDN) statutory profits understate the true strength and quality of its earnings. Earnings quality exceeding statutory profits moderately influences financial perception and investor sentiment.
10 May
Guardian Pharmacy Services, Inc. (GRDN) beat Q1 expectations strongly and filed a new shelf registration, potentially altering the bull case for the stock. Strong Q1 beat boosts financial performance and shelf registration enables future capital raises for expansion.
Guardian Pharmacy Services, Inc. (GRDN) released highlights from its Q1 earnings call, covering financial performance, operational updates, and forward guidance. Q1 earnings call highlights detail financial results and guidance with moderate influence on GRDN's performance and investor sentiment.
7 May
Guardian Pharmacy Services, Inc. (GRDN) released Q1 2026 earnings call summary highlighting quarterly financial results, operational updates, and forward guidance. Q1 earnings call summary reveals financial performance and strategic updates with moderate influence on investor sentiment and trajectory.
6 May
Guardian Pharmacy Services, Inc. (GRDN) reported first quarter 2026 financial results and updated full-year guidance. Quarterly earnings reports with updated full-year guidance significantly influence financial performance, investor sentiment, and market trajectory.
Guardian Pharmacy Services (GRDN) reported Q1 earnings and revenues that surpassed analyst estimates. Beating Q1 earnings and revenue estimates positively affects financial performance and market sentiment with moderate influence.
1 May
Guardian Pharmacy Services, Inc. (GRDN) prepares to release Q1 earnings, with focus on expected financial results, growth metrics, and factors influencing future performance. Upcoming Q1 earnings report will likely influence GRDN's financial performance and market sentiment to a moderate degree.
29 Apr
Guardian Pharmacy Services (GRDN) will report earnings next week, with Wall Street expecting growth. Upcoming earnings report with expected growth will moderately influence GRDN's financial performance expectations and investor sentiment.
2 Apr
Analysts have raised earnings estimates for Guardian Pharmacy Services (GRDN), signaling stronger expected financial performance and prompting buy recommendations. Upward earnings estimate revisions indicate moderately improved financial outlook, influencing investor sentiment and stock trajectory.
19 Mar
Guardian Pharmacy Services, Inc. (GRDN) announced the pricing of an upsized underwritten public offering of Class A common stock, increasing the size from initial plans to raise additional capital. Upsized public offering provides substantial capital influx, enabling growth initiatives and significantly influencing GRDN's financial trajectory and investor sentiment.
18 Mar
Guardian Pharmacy Services, Inc. (GRDN) announced the launch of an underwritten public offering of its Class A common stock. Launching an underwritten public offering enables major capital raising to fuel growth and directly impacts GRDN's financial position and investor sentiment.
11 Mar
Guardian Pharmacy Services Inc (GRDN) reported strong revenue growth in Q4 2025 earnings call highlights, alongside key financial metrics and future outlook. Strong Q4 2025 revenue growth indicates significant positive shift in GRDN's financial trajectory and investor sentiment.
Guardian Pharmacy Services, Inc. (GRDN) released Q4 2025 earnings call summary detailing financial results, operational updates, and forward guidance. Q4 earnings call summary discloses key financial metrics and strategic outlook significantly influencing investor sentiment and market performance.
Guardian Pharmacy Services, Inc. (GRDN) reported Q3 earnings with revenue up 12% to $45.2 million, net income of $3.1 million, and raised full-year guidance amid strong demand for institutional pharmacy services and expansion into new markets. Strong earnings beat and raised guidance signal significant positive shift in financial trajectory and investor confidence.
Guardian Pharmacy Services (GRDN) surpassed Q4 earnings and revenue estimates. Beating Q4 earnings and revenue estimates signals strong financial performance, likely boosting GRDN's stock price and investor sentiment.
Guardian Pharmacy Services, Inc. (GRDN) reported fourth quarter and full-year 2025 financial results, raising 2026 Adjusted EBITDA guidance. Raising 2026 Adjusted EBITDA guidance signals strong expected financial growth and boosts investor confidence.
Guardian Pharmacy Services, Inc. (GRDN) released Q4 earnings call highlights detailing financial performance, operational updates, and future outlook. Q4 earnings highlights impact financial performance and investor sentiment but are balanced by market factors.
Guardian Pharmacy Services Inc. (GRDN) reported Q4 net income and EPS figures alongside revenue in its earnings snapshot. Quarterly earnings snapshots moderately influence financial performance and investor sentiment without fundamentally altering long-term prospects.
5 Mar
Guardian Pharmacy Services, Inc. (GRDN) receives analyst rating upgrade to Buy, signaling strong growth potential in pharmacy services amid favorable market conditions. Analyst upgrade to Buy likely boosts investor sentiment and drives significant positive shift in GRDN's market performance.
9 Feb
Guardian Pharmacy Services, Inc. (GRDN) is set to report its financial results for the fourth quarter and full year of 2025. The company will also host a conference call to discuss these results, providing insights into its performance and future outlook. The financial results and conference call may moderately influence investor sentiment and provide insights into the company's performance.